LAS VEGAS, March 2, 2018 /PRNewswire/ --
Based on data provided by Arcview Market Research, legal cannabis sales in North America
totaled $6.7 billion in 2016 and are projected to grow at a compound annual growth rate of 25
percent to an estimated $20.2 billion by 2021. The demand of cannabis from legal markets is
expected to increase as more states legalize either recreational or medical use. Consumers in North
America spent over $53 billion in the legal and illegal cannabis markets combined in 2016.
According to another report from Arcview Market Research, the licensed cannabis stores are as profitable as Starbucks stores and
the recreational markets will double the size of the medical market by 2021. Chineseinvestors.com, Inc. (OTC: CIIX), CV
Sciences, Inc (OTC: CVSI), Freedom Leaf, Inc. (OTC: FRLF), GB Sciences, Inc. (OTC: GBLX), Isodiol International Inc. (OTC:
ISOLF).
A major portion of the legal cannabis industry Cannabidiol products. Cannabidiol, or CBD, is one of at least 113 active
cannabinoids identified in cannabis. The CBD market is growing rapidly in recent years due to CBD's medical benefits.
Sean Murphy, the Founder and Publisher of Hemp Business Journal, said: "Hemp Business Journal
estimates the total retail value of all hemp products sold in the U.S. to be at least $688 million
for 2016. We estimate the hemp industry will grow to $1.8 billion in sales by 2020, led by hemp
food, body care, and CBD-based products. The data demonstrates the hemp industry is growing quickly at 22% five year CAGR and
being led by food and body care products, with Hemp CBD products showing a 53% AGR."
Chineseinvestors.com, Inc. (OTCQB: CIIX) on February 28th announced the details of
the stock dividends related to the upcoming spinoff of all hemp-related assets including its China-based wholly owned foreign enterprise, CBD Biotechnology Co. Ltd. ("CBD Biotech") and its wholly owned
United States subsidiaries, ChineseHempOil.com, Inc. ("Chinese Hemp Oil") and Hemp Logic, Inc.
("Hemp Logic").
Last month, the Company's subsidiaries achieved combined sales of over $100,000.00 and are well
positioned to continue to achieve substantial growth into 2018 and beyond. CIIX plans to spin off all of its hemp related assets
including, but not limited to, CBD Biotech, Chinese Hemp Oil and Hemp Logic into a single private company (the "New Company")
with the goal being to bring the New Company into the public market in 12 to 18 months that follow. The New Company will issue
one share of stock in the New Company for every four shares of CIIX's common stock held by investors as of the date of the
spinoff, May 31, 2018.
According to CIIX's CEO, Warren Wang, "We want to provide our shareholders the opportunity to
take advantage of this dividend; therefore, we encourage holders of our preferred stock to convert into common prior to
May 31, 2018."
CIIX will continue to oversee the progress of the New Company. CIIX's CEO, Mr. Wang, and its CFO, Paul
Dickman will serve on the board of directors of the New Company. CIIX is also currently evaluating potential independent
board members for the New Company and individuals to join the management team.
CIIX has enjoyed success in helping to support various startup companies through its advertising and public relation related
support services. Many of those startup companies have gone on to achieve strong stock prices. We look forward to the Company's
spin off continuing this track record of success. Chinese Hemp Oil, Hemp Logic and CBD Biotech represent the Company's only
involvement in the hemp industry, with its hemp-based CBD products; therefore, spinning off these entities will completely remove
the parent, CIIX, from its involvement in the hemp industry, leaving the New Company to capitalize on the continuously growing
hemp industry and other complimentary ventures.
"This is a great time to spin off CIIX's CBD focused assets as we continue to explore new ways to expand its core financial
services business, including its recent move into the cryptocurrency and blockchain technology industry," according to
ChineseInvestors.com, Inc.'s CFO Paul Dickman.
CV Sciences, Inc (OTCQB: CVSI), located in San Diego, California and Las Vegas, Nevada, focuses on drug development activities on products containing cannabidiol (CBD) as the
active pharmaceutical ingredient, and also is engaged in the manufacturing, marketing and sale of end consumer products
containing CBD, which is refined into its own PlusCBD Oil™ brand. CV Sciences' Pharmaceutical Division is developing
synthetically‐formulated cannabidiol‐based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for
drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. CV Sciences has achieved promising
preclinical results in the development of cannabinoid medicines for treatment of a range of medical conditions. CV Sciences'
Consumer Products Division delivers botanical‐based cannabidiol products that enhance quality of life. Currently distributed
nationally in health food stores, health care provider's offices and online, each consumer products brand is backed by a formal
safety review, growing body of case reports, and physician's recommendations. Recently, the company announced that it will be
presenting at 30th Annual ROTH Conference. The Conference is being held on March 11-14, 2018 at The
Ritz-Carlton in Dana Point, California.
Freedom Leaf, Inc. (OTCQB: FRLF) is a leading, go-to resource in the cannabis, medical and recreational marijuana, CBD
and industrial hemp industries. On January 31, 2018, the company announced a joint venture supply
partnership with NutraFuels, Inc. Freedom Leaf CEO Cliff Perry announced, "We have created a
strong relationship with NutraFuels as they assisted us in the formulation, blending and private labeling our Ayurvedic
Breathable Vapor Oils that are the flagship product in our Hempology ® line of Full Spectrum Whole-Plant Hemp Extracts."
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production
methods; as well as biopharmaceutical research and development. Recently, the company announced a new agreement with the Colorado
Hemp Project to develop and cultivate boutique genetics and new strains of hemp which will provide the key ingredient in
proprietary CBD formulations. The mission statement of the Colorado Hemp Project is: an organic hemp farm consulting agency that
works with local farmers and municipalities across the globe to bring hemp cultivars and resources to the communities that need
it the most, with the sole intention of healing the planet by accelerating the establishment of local, sustainable hemp farms and
companies everywhere. GB Sciences believes that hemp will provide an important palette upon which important compounds can be
created, and believes that, ultimately, hemp will provide a relatively inexpensive source of important and beneficial
cannabinoids. GB Sciences will breed CBD into the genetics of the hemp plants and then analyze and optimize results.
Isodiol International Inc. (OTC: ISOLF) is the market leader in pharmaceutical grade phytochemical compounds and the
industry leader in the manufacturing and development of CBD consumer products. On February 15,
2018, the company announced that it has entered into a Definitive Agreement to acquire 100% of Canadian National Pharma
Group Inc., a pharmaceutical manufacturing company. Isodiol previously announced on Dec. 6th, 2017
the agreement to acquire an initial stake representing 25% equity of CN Pharma. The company purchased the remaining 75% equity
and is excited to establish CN Pharma as a wholly owned subsidiary. Once approved by Health Canada, CN Pharma will be licensed to
process and manufacture controlled substances, handle all cannabis and hemp derivatives, import and export oils and isolates,
prepare various formulation and mixtures, participate in research or testing activities, and conduct new product and drug
development.
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials
for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the
information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting
high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com
does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along
with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our
unique financial newswire and media platform. For chineseinvestors.com Inc. financial news dissemination and PR services,
FinancialBuzz.com expects to be compensated three thousand dollars by the company. Our fees may be
either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination
thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on
or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments
for financial news PR advertising. FinancialBuzz.com has signed a two year agreement with chineseinvestors.com Inc. for one
hundred thousand restricted common shares for continued financial news dissemination and PR services. FinancialBuzz.com does not
undertake to update any of the information on the editorial or Site or continue to post information about any companies the
information contained herein is not intended to be used as the basis for investment decisions and should not be considered as
investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any
security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions
expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes
electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own
independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By
accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may
be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to
purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any
investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a
particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation
needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment
decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are
subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness
are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.
For further information:
info@financialbuzz.com
+1-877-601-1879
URL: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com